In vitro potency testing of inactivated biologics: current situation in the E.E.C.

A whole series of regulations are currently being implemented in the European Economic Community in the field of biologics that are complementing the European Pharmacopoeia and widening its field of application. The object of these new regulations is to ensure a very high level of safety and efficacy, but unfortunately, they tend towards the increased use of animals for testing purposes. However, for ethical, economic and practical reasons, the number of animals used must be reduced which makes the development of in vitro tests an important issue.

Development of animal recombinant DNA vaccine and its efficacy in foxes.

Rabies is prevalent in most parts of the world. An extensive reservoir of the disease is present in the population of wild animals. The fox in particular is a major vector of the disease in North America and Europe.

Oral vaccination of the fox against rabies using a live recombinant vaccinia virus.

Rabies, a viral disease affecting all warm-blooded animals, is prevalent in most parts of the world, where it propagates amongst wild animals, particularly the fox and dog. The public health and economic consequences of infection in man and livestock are well known. Attempts to control the disease by vaccinating wild carnivores with inactivated or attenuated rabies virus remain controversial, and we have instead evaluated here the potential of a recombinant vaccinia virus to protect foxes against the disease.